
Johnson & Johnson Highlights Promising Data on Investigational Autoantibody Drug Nipocalimab
SPRING HOUSE, PA — Johnson & Johnson has unveiled groundbreaking findings on nipocalimab, an investigational FcRn blocker, in a recent publication in mAbs. The study showcases the drug’s high-affinity binding capabilities …
Johnson & Johnson Highlights Promising Data on Investigational Autoantibody Drug Nipocalimab Read More